Global Multiplex Molecular Diagnostics Market Size study, byProduct (Analyzers, Software, Instruments, Centrifuge, Counting Chambers, Incubators), by Method (Real-time PCR, Nested PCR with Melt Curve Analysis, PCR with Low Density Microarray, PCR with Liq

Global Multiplex Molecular Diagnostics Market Size study, byProduct (Analyzers, Software, Instruments, Centrifuge, Counting Chambers, Incubators), by Method (Real-time PCR, Nested PCR with Melt Curve Analysis, PCR with Low Density Microarray, PCR with Liquid Phase Bead Array, PCR with Electrochemical Detection) by End-Use (Clinical Research Laboratory, Hospitals, Academic & Research Centers, Others)and Regional Forecasts 2022-2028

Global Multiplex Molecular Diagnostics Market is valued at approximately USD 22billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.5% over the forecast period 2022-2028.Multiplex molecular diagnostics are used to diagnose illnesses such as TB, chlamydia, the H1N1 virus, and others. End-user demand for multiplex molecular diagnostics is projected to rise as a result of the identification of such disorders.As the multiplex molecular diagnostic approach became more widely used, it simplified testing algorithms and laboratory workflow, resulting in a surge in multiplex molecular diagnostics sales.With the introduction of multiplex PCRs, multiplex molecular diagnostics havesignificantly increased diagnostic yield; the tests have become more sensitive than routine culture or antigen detection. As a result, sales of multiplex molecular diagnostics are generated in the market for multiplex molecular diagnostics. . The leading companies in the multiplex molecular diagnostics industry are making strategic collaborations to gain market share. Sherlock Biosciences and Binx Health recently announced a collaboration to produce the world's first quick point-of-care COVID-19 diagnostic tool based on CRISPR technology. Similarly, SpeeDx and Roche have collaborated to provide access to antibiotic resistance tests.With the introduction of multiplex PCRs, multiplex molecular diagnostics have greatly boosted diagnostic output; the tests have grown more sensitive than standard culture or antigen detection. This results in multiplex molecular diagnostics sales in the multiplex molecular diagnostics industry.The present multiplex molecular diagnostics test does have certain limitations. Multiplex molecular diagnostics cannot detect all probable infections in their current form, which may reduce sales of multiplex molecular diagnostics. New technical advancements are also propelling the growth of the multiplex molecular diagnostics industry.

The key regions considered for the global Multiplex Molecular Diagnostics marketstudy includeAsia Pacific, North America, Europe, Latin America, and Rest of the World.Over the projected period, North America is expected to be the leading revenue-generating region for the multiplex molecular diagnostics market. Demand for multiplex molecular diagnostics is expected to develop faster in this region than in others. Many reasons contribute to the high revenue generation in NA for multiplex molecular diagnostics market share, including well-developed high-tech diagnostic labs, the existence of a large number of important companies, and favourable research funding. Europe is expected to be the second most significant area for multiplex molecular diagnostics market due to an increase in the number of patient care and epidemiologic research undertaken in this region.

Major market players included in this report are:
BD
BioMérieux SA
GenMark Diagnostics, Inc
Hologic
Luminex Corporation
Sherlock biosciences
Binx Health
SpeeDx
Roche
Contextual Genomics
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

Analyzers
Software
Instruments
Centrifuge
Counting Chambers
Incubators

By Method:

Real-time PCR
Nested PCR with Melt Curve Analysis
PCR with Low Density Microarray
PCR with Liquid Phase Bead Array
PCR with Electrochemical Detection

By End-Use:

Clinical Research Laboratory
Hospitals
Academic & Research Centers
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Multiplex Molecular Diagnostics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

BD
BioMérieux SA
GenMark Diagnostics, Inc
Hologic
Luminex Corporation
Sherlock biosciences
Binx Health
SpeeDx
Roche
Contextual Genomics

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.